Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunomedics' investigational compound hA20, a humanized anti-CD20 monoclonal antibody, appears to be active and safe in patients with non-Hodgkin's lymphoma according to initial results from the company's phase I/II study.
Subscribe to our email newsletter
34 adult patients with documented CD20-positive B-cell non-Hodgkin’s lymphoma were enrolled and were infused once weekly for four weeks consecutively with 120, 200, 375, or 750 mg/m2 of hA20.
The overall objective response rate to hA20 was 61% with 26% of patients having a complete response. Other than mild to moderate transient infusion reactions, predominantly with the first infusion, no significant toxicity was reported.
Results of the study were presented at the 47th annual meeting of the American Society of Hematology.
“We are very encouraged by these preliminary results and are particularly enthused by the high proportion of complete responses in patients who received 120 mg/m2 of hA20, the lowest dose used in the trial,” commented Cynthia Sullivan, president and CEO. “We are in the process of formulating the optimal dose to bring the study to the next phase.”